Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
Physiological immune checkpoint pathways are important to regulate self-tolerance, limit immune reactions, and moderate autoimmunity. Various cancers are commonly exploiting these mechanisms to evade the host immune system by restraining a durable, efficient anti-tumor immune response. Immune checkpoints include, but are not limited to, the programmed death 1 (PD1) and the cytotoxic T-lymphocyte-associated protein-4 (CTLA4) axis, which are both druggable by monoclonal antibodies referred to as checkpoint inhibitors (CIs). To date, the anti-PD1 antibodies nivolumab and pembrolizumab are approved for relapsed or refractory classical Hodgkin lymphoma (cHL) due to high response rates with a favorable yet distinct safety profile, and other agents are under investigation. This review summarizes the available preclinical and clinical data including the toxicity and efficacy of different CIs in cHL. It also provides future perspectives based on ongoing clinical trials, potentially synergistic combinatory approaches, and their fit in the therapeutic landscape in cHL.
['Bröckelmann|Paul J|PJ|', 'Engert|Andreas|A|']
D000911:Antibodies, Monoclonal D061067:Antibodies, Monoclonal, Humanized D000970:Antineoplastic Agents D060908:CTLA-4 Antigen D002986:Clinical Trials as Topic D005858:Germany D006689:Hodgkin Disease D006801:Humans D000077594:Nivolumab D061026:Programmed Cell Death 1 Receptor D016896:Treatment Outcome D019139:Tumor Escape
Checkpoint inhibition Hodgkin lymphoma Clinical trials Immunotherapy